ABSTRACT
Resumen: La actual pandemia por Covid-19 (SARS-CoV-2) corresponde a una zoonosis viral altamente con tagiosa que ha requerido extremar las medidas de protección personal con el fin de disminuir la transmisión del virus, tanto en ambientes hospitalarios como fuera de ellos, siendo necesaria la adopción de estrictos métodos de aislamiento tanto de contacto como aerosoles. Esto ha reque rido la adopción de múltiples equipos de protección personal, dentro de los que se encuentran la protección ocular, mascarillas, escudo de protección facial, gorros, guantes, etcétera. Lo anterior ha generado un aumento en el daño de la barrera cutánea y, por lo tanto, la aparición de diversas dermatosis dentro de las que se encuentran dermatitis de contacto irritativa o alérgica, reaccio nes acneiformes, agravamiento de dermatosis previas, entre otras, cobrando así vital importancia el cuidado y restablecimiento de la barrera cutánea con medidas esenciales como aplicación de productos humectantes o emolientes y el correcto uso de los equipos en mención. No obstante, no solo se generan dermatosis derivadas del uso de equipos de protección personal, sino que tam bién, dentro del amplio espectro de manifestaciones dermatológicas que puede generar la enfer medad por Covid-19 propiamente tal, incluyendo compromiso cutáneo, piloso (efluvio telógeno) o ungueal (onicomadesis). Por otro lado pero no motivo de este artículo, el compromiso cutáneo puede corresponder a la primera expresión clínica de la enfermedad o ser un predictor de su evolu ción. Dentro de lo anterior encontramos la urticaria aguda, exantema maculo-papular, exantema varicela-like, erupción petequial, perniosis-like y lívedo reticularis como las principales formas de afección cutánea hasta el momento.
Abstract: The current Covid-19 pandemic (SARS-CoV-2) corresponds to a highly contagious viral zoonosis that has required to extreme measures in order to decrease the transmission of the virus in hospi tal settings and outside of them, requiring adoption of strict isolation methods, both contact and aerosols. This has required the adoption of multiple personal protective equipment, including eye protection, masks, face shield, medical caps, gloves, etc. The aforementioned has generated an in crease in the damage of the skin barrier, and therefore, the appearance of various dermatoses, among which are irritative o alergic contact dermatitis, acneiform reactions, aggravation of previous der matoses, and others, thus becoming vital protection and restoration of the skin barrier with mea sures such as the application of moisturizing or emollient products and the correct use of personal protection equipment. However, not only dermatoses are generated derived from the use of perso nal protection equipment, but also, within the wide spectrum of dermatological manifestations that Covid-19 disease itself can generate, including cutaneous, hairy involvement (telogen effluvium) or nail (onychomadesis). Cutaneous involvement may correspond to the first clinical expression of the disease or be a predictor of its evolution. Among the above we find acute urticaria, maculo-papular rash, chickenpox-like rash, petechial rash, perniosis-like, and livedo reticularis as the main forms of skin condition to date.
ABSTRACT
Drug rash with eosinophilia and systemic symptoms or DRESS Syndrome is a rare, serious and potentially fatal adverse drug reaction. It is characterized by widespread morbilliform and edematous skin lesions, associated with eosinophilia, lymphadenopathy and internal organ involvement and unusually associated with pulmonary symptoms. We report a 47-year-old male with DRESS syndrome, manifested with typical skin lesions and extensive pulmonary involvement, responding satisfactorily to systemic corticosteroids.
Subject(s)
Humans , Male , Middle Aged , Lung Diseases, Interstitial/chemically induced , Lung Diseases, Interstitial/pathology , Drug Hypersensitivity Syndrome/pathology , Penicillin G Benzathine/adverse effects , Dipyrone/adverse effects , Treatment Outcome , Adrenal Cortex Hormones/therapeutic use , Lung Diseases, Interstitial/drug therapy , Antipyretics/adverse effects , Drug Hypersensitivity Syndrome/drug therapy , Anti-Bacterial Agents/adverse effectsABSTRACT
BACKGROUND: The mortality of lung cancer (LC), increases each year in the world, in spite of any advances, in development of new drugs to advance stages of LC. The high incidence of LC has been associated with smoking habit, genetic diversity and environmental pollution. Antofagasta region has been reported to have the highest LC mortality rate in Chile and its inhabitants were exposed to arsenic in their drinking water in concentrations as high as 870 µg/L. Non-invasive techniques such as biomarkers (Automatic Quantitative Cytometry: AQC and DR70) and Auto Fluorescence Bronchoscopy (AFB) might be potentially useful as a supplementary diagnostic approach and early detection. Early detection is one of the most important factors to intervene and prevent cancer progression in LC. This is a work of an ongoing prospective bimodality cancer surveillance study in high risk LC volunteers. Enrolment was done in subjects from Antofagasta and Metropolitan regions. In addition, we enrolled subjects who were suspected of having lung cancer. AQC, DR70 and AFB were used as tools in the detection of pre-neoplastic (PNL) and neoplastic lesions (NL). RESULTS: Half of the samples, classified as suspicious by AFB, were confirmed as metaplasia or dysplasia by histopathology. For LC, DR70 showed a higher sensitivity (95.8%) and specificity (91.9%) than AQC. However, for PNL AQC showed a higher sensitivity (91.9%) than DR70 (27.3%), although both with low PPV values. As a pre screener, both biomarkers might be employed as complementary tools to detect LC, especially as serially combined tests, with a sensitivity of 60% and a PPV of 65.2%. Additionally, the use of parallel combined tests might support the detection of PNL (sensitivity 91.2%; PPV 49.1%). CONCLUSION: This work adds information on cellular and molecular biomarkers to complement imaging techniques for early detection of LC in Latin America that might contribute to formulate policies concerning screening of LC. Supported by INNOVA-CORFO, Chile.